Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation

Journal of Immunology

Volumn 178, Issue 10, 2007, Pages 6242-6251

  Pillai, Asha B ^a   George, Tracy I ^a   Dutt, Suparna ^a   Teo, Pearline ^a   Strober, Samuel ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PERFORIN; THYMOCYTE ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BONE MARROW TRANSPLANTATION; CD8+ T LYMPHOCYTE; COLON INJURY; CONTROLLED STUDY; DONOR; GRAFT VERSUS HOST REACTION; INFLAMMATION; LEUKEMIA; LYMPH NODE IRRADIATION; LYMPHOMA; MALE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR GROWTH;

EID: 34248172955     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.10.6242     Document Type: Article

References (29)

1. Ferrara, J. L. M., and J. H. Antin. 1999. The pathophysiology of graft-versus-host disease. In Hematopoietic Stem Cell Transplantation, 2nd Ed. E. D. Thomas, K. G. Blume, and S. J. Forman, eds. Blackwell Science, Malden, pp. 310-315.
2. Giralt, S., E. Estey, M. Albitar, K. van Biesen, G. Rondon, P. Anderlini, S. O'Brien, I. F. Khouri, J. Gajewski, R. Mehra, et al. 1997. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89: 4531-4536.
3. Khouri, I. F., M. Keating, M. Korbling, D. Przepiorka, P. Anderlini, S. O'Brien, S. Giralt, C. Ippoliti, B. von Wolff, J. Gajewski, et al. 1998. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J. Clin. Oncol. 16: 2817-2824.
4. Slavin, S., A. Nagler, E. Naparstek, Y. Kapelushnik, M. Aker, G. Cividalli, G. Varadi, M. Kirschbaum, A. Ackerstein, S. Samuel, et al. 1998. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91: 756-763.
5. Curtis, R. E., L. B. Travis, P. A. Rowlings, G. Socie, D. W. Kingma, P. M. Banks, E. S. Jaffe, G. E. Sale, M. M. Horowitz, R. P. Witherspoon, et al. 1999. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 94: 2208-2216.
6. Martin, P. J., J. A. Hansen, C. D. Buckner, J. E. Sanders, H. J. Deeg, F. R. Appelbaum, R. Clift, A. Fefer, and R. P. Witherspoon. 1985. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 66: 664-672.
7. Burnett, A. K., I. M. Hann, A. G. Robertson, M. Alcorn, B. Gibson, I. McVicar, L. Niven, S. Mackinnon, H. Hambley, and A. Morrison. 1988. Prevention of graft-versus-host disease by ex vivo T cell depletion: reduction in graft failure with augmented total body irradiation. Leukemia 2: 300-303.
8. Lowsky, R., T. Takahashi, Y. P. Liu, S. Dejbakhsh-Jones, F. C. Grumet, J. A. Shizuru, G. G. Laport, K. Stockerl-Goldstein, L. Johnston, R. Hoppe, et al. 2005. Protective conditioning for acute graft-versus-host disease. N. Engl. J. Med. 353: 1321-1331.
9. + T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: "natural suppressor" cells. J. Immunol. 167: 2087-2096.
10. Lan, F., D. Zeng, M. Higuchi, J. P. Higgins, and S. Strober. 2003. Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells. Biol. Blood Marrow Transplant. 9: 355-363.
11. + T cells reciprocally regulate acute graft versus host disease. J. Exp. Med. 189: 1073-1081.
12. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 9: 1144-1150.
13. + regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Exp. Med. 196: 389-399.
14. Hashimoto, D., S. Asakura, S. Miyake, T. Yamamura, L. Van Kaer, C. Liu, M. Tanimoto, and T. Teshima. 2005. Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells. J. Immunol. 174: 551-556.
15. Sonoda, K. H., M. Exley, S. Snapper, S. P. Balk, and J. Stein-Streilein. 1999. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J. Exp. Med. 190: 1215-1226.
16. Cui, J., T. Shin, T. Kawano, H. Sato, E. Kondo, I. Toura, Y. Kaneko, H. Koseki, M. Kanno, and M. Taniguchi. 1997. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 278: 1623-1626.
17. 1). J. Immunol. 123: 1181-1188.
18. + T cells in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation. Transplantation 60: 355-361.
19. Lan, F., D. Zeng, P. Huie, J. P. Higgins, and S. Strober. 2001. Allogeneic bone marrow cells that facilitate complete chimerism and eliminate tumor cells express both CD8 and T-cell antigen receptor-αβ. Blood 97: 3458-3465.
20. 7 integrin on donor CD4 T cells are required for the early migration to host mesenteric lymph nodes and acute colitis of graft-versus-host disease. Blood 106: 4009-4015.
21. Kaplan, D. H., B. E. Anderson, J. M. McNiff, D. Jain, M. J. Shlomchik, and W. D. Shlomchik. 2004. Target antigens determine graft-versus-host disease phenotype. J. Immunol. 173: 5467-5475.
22. Seino, K. I., and M. Taniguchi. 2005. Functionally distinct NK T cell subsets and subtypes. J. Exp. Med. 202: 1623-1628.
23. Terabe, M. S., J. Swann, E. Ambrosino, P. Sinha, S. Takaku, Y. Hayakawa, D. I. Godfrey, S. Ostrand-Rosenberg, M. J. Smyth, and J. A. Berzofsky. 2005. A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for downregulation of tumor immunosurveillance. J. Exp. Med. 202: 1627-1633.
24. Terabe, M. S., J. M. Matsui, M. Park, M. Mamura, N. Noben-Trauth, D. D. Donaldson, W. Chen, S. M. Wahl, S. Ledbetter, and B. Pratt. 2003. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198: 1741-1752.
25. Crowe, N. Y., J. M. Coquet, S. P. Berzins, K. Kyparissoudies, R. Keating, D. G. Pellici, Y. Hayakawa, D. I. Godfrey, and M. J. Smyth. 2005. Differential anti-tumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med. 202: 1279-1288.
26. Reddy, P., Y. Maeda, C. Liu, O. I. Krijanovski, R. Korngold, and J. L. M. Ferrara. 2005. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat. Med. 11: 1244-1249.
27. + T cells that survive irradiation regulate chronic graft-versus-host disease. Blood 104: 1565-1573.
28. Morecki, S., S. Panigrahi, G. Pizov, E. Yacovlev, Y. Gelfand, O. Eizik, and S. Slavin. 2004. Effect of KRN7000 on induced graft-vs-host disease. Exp. Hematol. 32: 630-637.
29. Morris, E. S., K. P. MacDonald, V. Rowe, T. Banovic, R. Kuns, A. L. Don, H. M. Bofinger, A. C. Burman, S. D. Olver, N. Kienzle, et al. 2005. NK T cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. J. Clin. Invest. 115: 3093-3103.